DGX241018P140000
- 0.47
- 0.000.00%
Quest Diagnostics Newsroom
Baird Adjusts Price Target on Quest Diagnostics to $155 From $154, Maintains Neutral
Evercore ISI Group Reinstates In-Line on Quest Diagnostics, Announces $165 Price Target
Evercore Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Quest Diagnostics: Hold Rating Affirmed Amid Balanced Risk/Reward Profile and Premium Valuation
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Quest Diagnostics Price Target Raised to $154.00/Share From $144.00 by Barclays
Quest Diagnostics Analyst Ratings
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $154
Barclays Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $154
Barclays Remains a Hold on Quest Diagnostics (DGX)
Barclays Raises Quest Diagnostics' Price Target to $154 From $144, Maintains Equalweight Rating
JPMorgan Adjusts Price Target on Quest Diagnostics to $173 From $155, Maintains Neutral Rating
Quest Diagnostics: Strong Performance and Growth Trajectory Justify Buy Rating
Piper Sandler Adjusts Price Target on Quest Diagnostics to $150 From $145, Maintains Neutral Rating
Quest Diagnostics Price Target Raised to $150.00/Share From $145.00 by Piper Sandler
Quest Diagnostics Analyst Ratings
Piper Sandler Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $150
Mizuho Securities Raises Quest Diagnostics' Price Target to $160 From $155
Maintaining Neutral Hold on Quest Diagnostics Amid Modest Growth and Pending Strategic Insights